Comparison 3. Efficacy ‐ febuxostat 120 mg/day versus placebo.

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Incidence of gout flares	2	479	Risk Ratio (M‐H, Fixed, 95% CI)	1.71 [1.26, 2.32]
1.1 28 days	1	76	Risk Ratio (M‐H, Fixed, 95% CI)	1.5 [0.91, 2.49]
1.2 8 weeks	1	403	Risk Ratio (M‐H, Fixed, 95% CI)	1.79 [1.23, 2.60]
2 Serum uric acid <6.0 mg/dL at final visit	2	356	Risk Ratio (M‐H, Fixed, 95% CI)	80.65 [16.04, 405.52]
2.1 28 days	1	69	Risk Ratio (M‐H, Fixed, 95% CI)	66.86 [4.26, 1050.04]
2.2 28 weeks	1	287	Risk Ratio (M‐H, Fixed, 95% CI)	85.84 [12.20, 603.82]
3 Change in serum uric acid concentration from baseline at final visit	2	472	Mean Difference (IV, Random, 95% CI)	‐5.31 [‐5.68, ‐4.94]
3.1 28 days	1	69	Mean Difference (IV, Random, 95% CI)	‐5.02 [‐5.60, ‐4.45]
3.2 28 weeks	1	403	Mean Difference (IV, Random, 95% CI)	‐5.44 [‐5.70, ‐5.17]